Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal.
Uzun
O
O
Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Anaissie
E J
EJ
D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000517:prevention & control; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002177:Candidiasis / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004198:Disease Susceptibility; D004333:Drug Administration Routes; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D017708:Leukocyte Transfusion; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications* / Q000276:immunology / Q000628:therapy; D009503:Neutropenia / Q000150:complications; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000935:Antifungal Agents; D016298:Hematopoietic Cell Growth Factors; D014230:Triazoles; D000666:Amphotericin B